Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05186805 · ClinicalTrials.gov registry record · Phase 2
Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Organon and.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 10
- Study locations
NCT05186805 is a Phase 2 study of Atopic Dermatitis that has completed, run by Organon and. The registered enrollment target is 36 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (94% lower). The trial reports 10 study locations across 7 states.
The verdict
NCT05186805, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic dermatitis
Conditions Studied
Interventions
- DRUG Tapinarof cream, 1%
Study Locations (10)
Florida
- Dermavant Investigative Site - Coral Gables
- Dermavant Investigative Site - Hialeah
- Dermavant Investigative Site - Miami Lakes
Texas
- Dermavant Investigative Site - Houston
- Dermavant Investigative Site - San Antonio
California
- Dermavant Investigative Site - Thousand Oaks
Colorado
- Dermavant Investigative Site - Centennial
Illinois
- Dermavant Investigative Site - Chicago
South Carolina
- Dermavant Investigative Site - Summerville
Alberta
- Dermavant Investigative Site - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-11-15 |
| Est. Completion | 2022-08-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05186805
The ClinicalTrials.gov registry entry for NCT05186805 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (94% lower). The listed sponsor is Organon and, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Tapinarof cream, 1% is the first listed.
NCT05186805 reports 10 study locations spanning 7 distinct geographic areas - top geographies include Florida, Texas, California.
Frequently Asked Questions
What is clinical trial NCT05186805 about?
NCT05186805 is a clinical study titled "Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis". This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in pediatric subjects with atopic dermatitis
What is the current status of trial NCT05186805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2021-11-15. Estimated completion is 2022-08-24.
What conditions does trial NCT05186805 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT05186805?
The interventions under investigation include: Tapinarof cream, 1% (DRUG).
Who is sponsoring clinical trial NCT05186805?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05186805 being conducted?
This trial has 10 study locations across California, Colorado, Florida, Illinois, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.